2017.09-2021.07 复旦大学药剂学, 博士
2014.09-2017.07 山东大学药物化学, 硕士
2010.09-2014.07 山东农业大学制药工程/工商管理, 学士
2026.04-至今 复旦大学药学院，助理教授/研究员；克服递药屏障高端制剂全国重点实验室PI
2026.03-至今 复旦大学附属上海市闵行区中心医院，助理研究员
2023.03-2026.02 麻省理工学院化学院, Research Affiliate
2022.12-2026.02 哈佛大学医学院布莱根妇女医院, 博士后
2022.02-2022.12 耶鲁大学医学院, 博士后
2021.07-2022.01 上海交通大学医学院/上海市肿瘤研究所, 助理研究员
1. 国家海外高层次人才引进青年项目，2025-2027，主持
2.上海市白玉兰人才计划青年项目，2025-2027，主持
3.复旦大学引进人才科研基金，2026-2029，主持
4.北京大学区域光纤通信网与新型光通信系统国家重点实验室，开放课题，2024GZKF13, 供体-受体型有机光电分子用于近红外 II 区荧光影像指导的胶质母细胞瘤光动力治疗，2024-2025，主持
5.美国心脏协会 (AHA)，博士后基金，23POST1029102, Universal human induced pluripotent stem cells-derived cardiac progenitor cells for cardiomyopathy disease treatment，2023-2024，主持
2025 中国分析测试协会分析测试科学奖一等奖 (6/8)
2025 中国药学会科学技术二等奖 (4/6)
2023 美国AHA fellowship
2021 2021年药剂学年会暨青年论文报告奖
2026-至今 Science Bulletin，青年编委
2025-至今 Life Conflux, 编委
2025-至今 PhotoniX，青年编委/Associate editor in biomedical imaging
2025-至今 Nano-Micro Letters, 青年编委
2025-至今 Materials Today Bio, 青年编委
2023-至今 Military Medical Research, 科学编辑
1. 基于光学或放射性核素成像的可视化递药系统构建
2. 基于光、声或放射疗法的肿瘤疫苗和CAR-免疫细胞设计
3. 生理屏障类器官构建及药物克服生理屏障机制研究
主要聚焦于可视化递药系统研究。通过揭示供体-受体（D-A）型分子的空间构象与其光物理性质之间的关系，提出基于分子空间构象的拉曼散射、荧光发射新机制，指导诊疗一体化分子探针设计和可视化递药系统构建，实现术中超灵敏无基底拉曼成像和NIR-II荧光成像技术引导精准诊疗，提高光学分子影像探针在体内诊断的灵敏度和生物安全性。以第一或通讯作者（含共同）在Nature Biotechnology等期刊发表论文多篇，ESI高被引论文1篇，杂志亮点报道1篇，授权中国发明专利5项。
1. Xiang Chen#, Zhanming Lin#, Yongjun Mo#, Jun Hou#, Hongjie Su, Ruiqing Mo, Nuo Cheng, Zhenghui Li, Feng Huang, Xi Yang, Sihan Wen, Liang Lu*, Xinyu Nie*, Shuai Gao*, Qikai Hua*. Indolicidin-decorated photosensitizer for enhanced antibacterials and accelerated diabetic wound healing. Advanced Materials, 2026, accept.
2. Shuai Gao#, Yongming Zhang#, Kai Cui#, Sihang Zhang, Yuanyuan Qiu, Yunhui Liao, Haoze Wang, Sheng Yu, Liyang Ma, Hongzhuan Chen, Minbiao Ji, Xiaohong Fang*, Wei Lu*, Zeyu Xiao*. Self-stacked small molecules for ultrasensitive, substrate-free Raman imaging in vivo. Nature Biotechnology, 2025, 43(6): 936-947.
3. Xiang Chen#, Zhanming Lin#, Nuo Cheng#, Yongjun Mo#, Liang Lu, Jun Hou, Hongjie Su, Zhenghui Li, Xinyu Nie*, Shuai Gao*, Qikai Hua*. Recent advances in NIR-II photothermal and photodynamic therapies for drug-resistant wound infections. Materials Today Bio, 2025, 32: 101871.
4. Hangqi Luo, Shuai Gao*. Recent advances in fluorescence imaging-guided photothermal therapy and photodynamic therapy for cancer: From near-infrared-I to near-infrared-II.Journal of Controlled Release, 2023, 362, 425-445.
5. Shuai Gao#, Sheng Yu#, Yongming Zhang#, Aihua Wu#, Sihang Zhang, Guoguang Wei, Hao Wang*, Zeyu Xiao*, Wei Lu*. Molecular engineering of near-infrared-II photosensitizers with steric hindrance effectfor image-guided cancer photodynamic therapy. Advanced Functional Materials,2021, 31, 2008356.
6. Zihua Hu#，Binbin Zheng#，Jiaojiao Xu#，Shuai Gao#，Wei Lu*. An albumin-bound drug conjugate of paclitaxel and the indoleamine-2,3-dioxygenase inhibitor for enhanced cancer chemo-immunotherapy. Nanotechnology, 2020, 31(29): 295101.
7. Shuai Gao#, Guoguang Wei#, Sihang Zhang#, Binbin Zheng, Jiaojiao Xu, Gaoxian Chen, Mingwang Li, Shaoli Song, Wei Fu, Zeyu Xiao*, Wei Lu*. Albumin tailoring fluorescence and photothermal conversion effect of near-infrared-II fluorophore with aggregation-induced emission characteristics. Nature Communications,2019,10(1), 2206.
8. Shuai Gao, Jie Zang, Qianwen Gao, Xuewu Liang, Qin’ge Ding, Xiaoyang Li, Wenfang Xu, C. James Chou, Yingjie Zhang*. Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine based zinc binding groups. Bioorganic & Medicinal Chemistry, 2017, 25(12), 2981-2994.
9. Shuai Gao, Xiaoyang Li, Jie Zang, Wenfang Xu*, Yingjie Zhang*. Preclinical and clinical studies of Chidamide (CS055/HBI-8000), an orally available subtype-selective HDAC inhibitor for cancer therapy. Anti-Cancer Agents in Medicinal Chemistry, 2017, 17(6), 802-812.
